Public Health provides a welcome update on the global situation with rubella, congenital rubella syndrome (CRS), and rubella immunization. There has been significant progress both in use of rubella vaccine and in surveillance for rubella and CRS in recent years. In 1996, 78 of 214 reporting countries/territories (36%) were using rubella vaccine routinely (2). This new Revista/Journal article indicates that 124 of them (58%) are now using the vaccine, an increase of more than 50% in their number in just 6 years.
Two WHO regions, the European Region and the Region of the Americas, have taken the lead in establishing targets for rubella/CRS control or elimination. In 1984 the European Region adopted a target of eliminating indigenous rubella and CRS, and more than 80% of the countries in the European Region are now using rubella vaccine in their immunization programs.
In the Americas a Hemispheric goal of measles elimination by 2000 was established and implemented (5) . As progress was made in measles elimination, interest in use of rubella vaccine began to increase (6) . The lead in use of rubella vaccine was taken by the countries of the English-speaking Caribbean, where many countries included rubella vaccine in their efforts to eliminate measles. The strategy in the Caribbean included two major components: (1) mass vaccination of males and females up to age 40 with combined measles-rubella (MR) or measles-mumps-rubella (MMR) vaccine, to provide protection to those imminently at risk of a rubella-infected pregnancy, and (2) introduction of rubella vaccine into the regular schedule of infant/young child immunization (7) .
The strategy in the Caribbean was effective both in planning and in reality. Transmission models and economic models indicated that the combined measles/rubella elimination strategy would be effective and cost-effective. Reality has borne this out: Measles and rubella are no longer indigenous diseases in the English-speaking Caribbean.
Reflecting continuing progress in Western Hemisphere measles elimination and growing interest in use of rubella vaccine, in September 2003 the Directing Council of the Pan American Health Organization approved a resolution calling for Member States to eliminate rubella and CRS by the year 2010 (8, 9) . Achieving that target in the Americas will require modification of rubella elimination strategies in several countries that currently use rubella vaccine only in selected groups or only in routine childhood immunizations, so as to ensure that women of childbearing age are protected and that transmission is interrupted (10) .
The Region of the Americas has been at the forefront in reaching many important immunization goals, including polio eradication and measles elimination. Eliminating rubella and CRS from the Western Hemisphere will be another instance of the exemplary achievements of the Region.
